Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results

As Part A of the ongoing phase I UNIVERSAL trial, researchers evaluated safety and tolerability of escalating doses of ALLO-715, a first-in-class allogeneic anti-BCMA CAR T-cell therapy designed to minimize rejection rates and incidence of graft-versus-host disease. A total of 43 patients with relapsed/refractory multiple myeloma received lymphodepletion with an anti-CD52 antibody (ALLO-647), which was also evaluated for safety. Of those who received ALLO-647 as part of their lymphodepletion regimen, 70.8% had a response. Regarding ALLO-715, grade ≥ 3 adverse events were seen in 88% of patients. Rates for cytokine release syndrome, neurotoxicity, and infections also are reported, as is median duration of response.